199 related articles for article (PubMed ID: 20371743)
21. The +37 kb Cebpa Enhancer Is Critical for Cebpa Myeloid Gene Expression and Contains Functional Sites that Bind SCL, GATA2, C/EBPα, PU.1, and Additional Ets Factors.
Cooper S; Guo H; Friedman AD
PLoS One; 2015; 10(5):e0126385. PubMed ID: 25938608
[TBL] [Abstract][Full Text] [Related]
22. The trithorax protein partner menin acts in tandem with EZH2 to suppress C/EBPα and differentiation in MLL-AF9 leukemia.
Thiel AT; Feng Z; Pant DK; Chodosh LA; Hua X
Haematologica; 2013 Jun; 98(6):918-27. PubMed ID: 23349306
[TBL] [Abstract][Full Text] [Related]
23. CTNNA1 hypermethylation, a frequent event in acute myeloid leukemia, is independently associated with an adverse outcome.
Li M; Gao L; Li Z; Sun J; Zhang H; Duan H; Ma Y; Wang C
Oncotarget; 2016 May; 7(21):31454-65. PubMed ID: 27129146
[TBL] [Abstract][Full Text] [Related]
24. The presence of C/EBPα and its degradation are both required for TRIB2-mediated leukaemia.
O'Connor C; Lohan F; Campos J; Ohlsson E; Salomè M; Forde C; Artschwager R; Liskamp RM; Cahill MR; Kiely PA; Porse B; Keeshan K
Oncogene; 2016 Oct; 35(40):5272-5281. PubMed ID: 26996668
[TBL] [Abstract][Full Text] [Related]
25. Gain-of-Function Effects of N-Terminal CEBPA Mutations in Acute Myeloid Leukemia.
Schmidt L; Heyes E; Grebien F
Bioessays; 2020 Feb; 42(2):e1900178. PubMed ID: 31867767
[TBL] [Abstract][Full Text] [Related]
26. Effects of age on the posttranscriptional regulation of CCAAT/enhancer binding protein alpha and CCAAT/enhancer binding protein beta isoform synthesis in control and LPS-treated livers.
Hsieh CC; Xiong W; Xie Q; Rabek JP; Scott SG; An MR; Reisner PD; Kuninger DT; Papaconstantinou J
Mol Biol Cell; 1998 Jun; 9(6):1479-94. PubMed ID: 9614188
[TBL] [Abstract][Full Text] [Related]
27. Post-transcriptional modulation of C/EBPα prompts monocytic differentiation and apoptosis in acute myelomonocytic leukaemia cells.
Yoshida H; Imamura T; Fujiki A; Hirashima Y; Miyachi M; Inukai T; Hosoi H
Leuk Res; 2012 Jun; 36(6):735-41. PubMed ID: 22349414
[TBL] [Abstract][Full Text] [Related]
28. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
[TBL] [Abstract][Full Text] [Related]
29. Deregulation of tumor suppressive ASXL1-PTEN/AKT axis in myeloid malignancies.
Cao L; Xia X; Kong Y; Jia F; Yuan B; Li R; Li Q; Wang Y; Cui M; Dai Z; Zheng H; Christensen J; Zhou Y; Wu X
J Mol Cell Biol; 2020 Sep; 12(9):688-699. PubMed ID: 32236560
[TBL] [Abstract][Full Text] [Related]
30. Runx1 deletion or dominant inhibition reduces Cebpa transcription via conserved promoter and distal enhancer sites to favor monopoiesis over granulopoiesis.
Guo H; Ma O; Speck NA; Friedman AD
Blood; 2012 May; 119(19):4408-18. PubMed ID: 22451420
[TBL] [Abstract][Full Text] [Related]
31. Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies.
Ye Y; McDevitt MA; Guo M; Zhang W; Galm O; Gore SD; Karp JE; Maciejewski JP; Kowalski J; Tsai HL; Gondek LP; Tsai HC; Wang X; Hooker C; Smith BD; Carraway HE; Herman JG
Cancer Res; 2009 Nov; 69(21):8482-90. PubMed ID: 19826047
[TBL] [Abstract][Full Text] [Related]
32. Translational control of C/EBPalpha and C/EBPbeta isoform expression.
Calkhoven CF; Müller C; Leutz A
Genes Dev; 2000 Aug; 14(15):1920-32. PubMed ID: 10921906
[TBL] [Abstract][Full Text] [Related]
33. Cross-talk between regulators of myeloid development: C/EBPalpha binds and activates the promoter of the PU.1 gene.
Kummalue T; Friedman AD
J Leukoc Biol; 2003 Sep; 74(3):464-70. PubMed ID: 12949251
[TBL] [Abstract][Full Text] [Related]
34. Activator protein 2 alpha (AP2alpha) suppresses 42 kDa C/CAAT enhancer binding protein alpha (p42(C/EBPalpha)) in head and neck squamous cell carcinoma.
Bennett KL; Romigh T; Arab K; Teresi RE; Tada Y; Eng C; Plass C
Int J Cancer; 2009 Mar; 124(6):1285-92. PubMed ID: 19089912
[TBL] [Abstract][Full Text] [Related]
35. Dependence on Myb expression is attenuated in myeloid leukaemia with N-terminal CEBPA mutations.
Volpe G; Cauchy P; Walton DS; Ward C; Blakemore D; Bayley R; Clarke ML; Schmidt L; Nerlov C; Garcia P; Dumon S; Grebien F; Frampton J
Life Sci Alliance; 2019 Apr; 2(2):. PubMed ID: 30877232
[TBL] [Abstract][Full Text] [Related]
36. C/EBPγ deregulation results in differentiation arrest in acute myeloid leukemia.
Alberich-Jordà M; Wouters B; Balastik M; Shapiro-Koss C; Zhang H; Di Ruscio A; Radomska HS; Ebralidze AK; Amabile G; Ye M; Zhang J; Lowers I; Avellino R; Melnick A; Figueroa ME; Valk PJ; Delwel R; Tenen DG
J Clin Invest; 2012 Dec; 122(12):4490-504. PubMed ID: 23160200
[TBL] [Abstract][Full Text] [Related]
37. Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway.
Li Y; Gao L; Luo X; Wang L; Gao X; Wang W; Sun J; Dou L; Li J; Xu C; Wang L; Zhou M; Jiang M; Zhou J; Caligiuri MA; Nervi C; Bloomfield CD; Marcucci G; Yu L
Blood; 2013 Jan; 121(3):499-509. PubMed ID: 23223432
[TBL] [Abstract][Full Text] [Related]
38. CCAAT/enhancer binding protein alpha (C/EBPalpha) and C/EBPalpha myeloid oncoproteins induce bcl-2 via interaction of their basic regions with nuclear factor-kappaB p50.
Paz-Priel I; Cai DH; Wang D; Kowalski J; Blackford A; Liu H; Heckman CA; Gombart AF; Koeffler HP; Boxer LM; Friedman AD
Mol Cancer Res; 2005 Oct; 3(10):585-96. PubMed ID: 16254192
[TBL] [Abstract][Full Text] [Related]
39. The AML-associated K313 mutation enhances C/EBPα activity by leading to C/EBPα overexpression.
Gentle IE; Moelter I; Badr MT; Döhner K; Lübbert M; Häcker G
Cell Death Dis; 2021 Jul; 12(7):675. PubMed ID: 34226527
[TBL] [Abstract][Full Text] [Related]
40. Transcription factor C/EBPα-induced microRNA-30c inactivates Notch1 during granulopoiesis and is downregulated in acute myeloid leukemia.
Katzerke C; Madan V; Gerloff D; Bräuer-Hartmann D; Hartmann JU; Wurm AA; Müller-Tidow C; Schnittger S; Tenen DG; Niederwieser D; Behre G
Blood; 2013 Oct; 122(14):2433-42. PubMed ID: 23974200
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
